Earl Martin, DO
Family Medicine · Tomball, TXNPI 1336295344
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 68.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $7,138 and has fallen 83.7% since, to $1,164 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- AbbVie$547
- Novo Nordisk$537
- AstraZeneca$314
- Lilly USA, LLC$296
- Novartis$268
- plus $2K from 28 others
Across 1,772 payments — averaging $3481.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$2.4M
- Sanofi Pasteur Inc.$1.5M
- Emergent Biosolutions Inc.$1.4M
- Eli Lilly$782K
- Pfizer$27K
- AstraZeneca$27K
- plus $5K from 1 others
What the payments were for
- Speaking & faculty fees$7,38056%
- Travel & lodging$1031%
- Food & beverage$5,52542%
- Education$691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 126 | $8,892 |
| AbbVie(2 entities) | 32 | $547 |
| Novo Nordisk | 36 | $537 |
| AstraZeneca | 20 | $314 |
| Lilly USA, LLC | 18 | $296 |
| Novartis | 16 | $268 |
| GSK | 15 | $247 |
| Aytu Biopharma, Inc. | 22 | $207 |
| Antares Pharma, Inc. | 12 | $207 |
| Radius Health, Inc. | 7 | $151 |
| Boehringer Ingelheim | 7 | $142 |
| Merck | 7 | $133 |
| Teva Pharmaceuticals USA, Inc. | 6 | $122 |
| Johnson & Johnson | 5 | $120 |
| Arbor Pharmaceuticals, Inc. | 8 | $115 |
| IBSA Pharma Inc. | 7 | $107 |
| Tolmar, Inc. | 5 | $87 |
| Abbott | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $75 |
| Clarus Therapeutics Inc. | 5 | $67 |
| Acerus Pharmaceuticals Corporation | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 2 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$7,505
How this compares
$13,077 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 176 | $200,806 |
| FarxigaDapagliflozin Propanediol | 46 | $52,706 |
| TrulicityDulaglutide | 28 | $40,413 |
| RybelsusSemaglutide | 20 | $36,561 |
| JardianceEmpagliflozin | 28 | $36,558 |
| Repatha SureclickEvolocumab | 50 | $30,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $30,380 |
| XareltoRivaroxaban | 17 | $28,174 |
| JatenzoTestosterone Undecanoate | 26 | $27,081 |
| OzempicSemaglutide | 24 | $24,029 |
| EliquisApixaban | 17 | $23,655 |
| MyrbetriqMirabegron | 19 | $20,903 |
| VascepaIcosapent Ethyl | 21 | $20,507 |
| EntrestoSacubitril/Valsartan | 12 | $16,105 |
| GemtesaVibegron | 19 | $13,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $296 | $241,218204 claims |
| Novo NordiskRybelsus, Ozempic | $537 | $60,59044 claims |
| AstraZenecaFarxiga, Symbicort | $314 | $55,85961 claims |
| Boehringer IngelheimJardiance | $142 | $36,55828 claims |
| GSKTrelegy Ellipta | $247 | $30,38041 claims |
| Johnson & JohnsonXarelto | $120 | $28,17417 claims |
| Clarus Therapeutics Inc.Jatenzo | $67 | $27,08126 claims |
| PfizerEliquis | $15 | $23,65517 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $20,90319 claims |
| NovartisEntresto | $268 | $16,10512 claims |
| AbbVieSynthroid | $547 | $4,79847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Tomball
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.